US

Supplying Kidneys

A market that allows payment for human kidneys should be established on a trial basis to help extend the lives of patients with kidney disease.

Responses weighted by each expert's confidence

Participant University Vote Confidence Bio/Vote History
Alesina
Alberto Alesina
Harvard
Agree
7
Bio/Vote History
Altonji
Joseph Altonji
Yale Did Not Answer Bio/Vote History
Auerbach
Alan Auerbach
Berkeley
Uncertain
5
Bio/Vote History
Autor
David Autor
MIT
No Opinion
Bio/Vote History
Not enough info to answer. Not in favor of a kidney market that sells to highest bidder. Other ideas maybe. Question is not actionable.
Banerjee
Abhijit Banerjee
MIT
Disagree
8
Bio/Vote History
That would mean valuing people's lives by their incomes. We already do that but moving further in that direction seems wrong.
Bertrand
Marianne Bertrand
Chicago
Agree
3
Bio/Vote History
Brunnermeier
Markus Brunnermeier
Princeton
Agree
6
Bio/Vote History
It is important that the market is "well regulated" in order to avoid abuse and exploitation of the vulnerables.
Chetty
Raj Chetty
Harvard
Uncertain
1
Bio/Vote History
Chevalier
Judith Chevalier
Yale
Strongly Agree
9
Bio/Vote History
This certainly may have unintended consequences but it is hard to fault attempting to create more supply.
Currie
Janet Currie
Princeton
Uncertain
5
Bio/Vote History
Cutler
David Cutler
Harvard
Strongly Disagree
6
Bio/Vote History
Deaton
Angus Deaton
Princeton
Strongly Disagree
8
Bio/Vote History
Duffie
Darrell Duffie
Stanford
Agree
3
Bio/Vote History
Under strong governance that mitigates exploitation, this market may save lives on mutually consenting terms.
Edlin
Aaron Edlin
Berkeley
Uncertain
7
Bio/Vote History
Dangerous ground, but a well-regulated experiment could be beneficial. Payments to fill out donor cards might increase supply, for example
Eichengreen
Barry Eichengreen
Berkeley
Uncertain
1
Bio/Vote History
A market with or without subsidies for low income patients?
Einav
Liran Einav
Stanford
Strongly Agree
7
Bio/Vote History
Fair
Ray Fair
Yale Did Not Answer Bio/Vote History
Finkelstein
Amy Finkelstein
MIT
Agree
8
Bio/Vote History
Goldberg
Pinelopi Goldberg
Yale Did Not Answer Bio/Vote History
Greenstone
Michael Greenstone
University of Chicago
Agree
8
Bio/Vote History
Hall
Robert Hall
Stanford
Uncertain
9
Bio/Vote History
Hard to know because we don't have much of an understanding of why people make organ gifts.
Hart
Oliver Hart
Harvard
Agree
8
Bio/Vote History
I'd like to see it but I'm not sure the public is ready. Also would insurance cover this? Would people be able to top up (presumably)?
Holmström
Bengt Holmström
MIT
Disagree
5
Bio/Vote History
Hoxby
Caroline Hoxby
Stanford
Uncertain
8
Bio/Vote History
Would improve allocative efficiency but means- and health-conditioned vouchers would presumably have to be used to address ethical concerns.
Hoynes
Hilary Hoynes
Berkeley
Agree
8
Bio/Vote History
Judd
Kenneth Judd
Stanford
Strongly Agree
10
Bio/Vote History
There is no reason to block this voluntary exchange. There may be unique challenges in applying laws against fraud, but nothing too hard.
Kaplan
Steven Kaplan
Chicago Booth
Uncertain
8
Bio/Vote History
Kashyap
Anil Kashyap
Chicago Booth
Agree
7
Bio/Vote History
Klenow
Pete Klenow
Stanford
Agree
3
Bio/Vote History
Levin
Jonathan Levin
Stanford Did Not Answer Bio/Vote History
Maskin
Eric Maskin
Harvard
Agree
7
Bio/Vote History
Nordhaus
William Nordhaus
Yale
Agree
5
Bio/Vote History
Perhaps experiments in different regimes better idea.
Obstfeld
Maurice Obstfeld
Berkeley
Uncertain
1
Bio/Vote History
Saez
Emmanuel Saez
Berkeley Did Not Answer Bio/Vote History
Samuelson
Larry Samuelson
Yale
Disagree
6
Bio/Vote History
We need to rationalize our organ allocation mechanism, but a market is not the only way, and is not obviously the best way.
Scheinkman
José Scheinkman
Columbia University
Agree
6
Bio/Vote History
Schmalensee
Richard Schmalensee
MIT
Uncertain
7
Bio/Vote History
How to deal with donors who don't understand risks, increased incentives to steal & import, perceived inequities...? Not simple.
Shapiro
Carl Shapiro
Berkeley
Agree
8
Bio/Vote History
Experiments seem valuable here, using health outcomes as our metric. Matching donors and recipients based in part on payment may be helpful.
Shimer
Robert Shimer
University of Chicago
Strongly Agree
7
Bio/Vote History
The biggest impact would be to increase kidney supply, so few obvious losers from this policy
Stokey
Nancy Stokey
University of Chicago
Uncertain
1
Bio/Vote History
It would surely save lives of those with kidney disease. It would probably have unintended consequences as well.
Thaler
Richard Thaler
Chicago Booth
Uncertain
5
Bio/Vote History
How should we incorporate the fact that nearly all non-economists hate this idea? Do we declare them wrong and proceed?
Udry
Christopher Udry
Northwestern
Strongly Agree
1
Bio/Vote History
As an economist, I strongly agree that there would be tremendous gains. But I'm uncertain of the appropriate bounds on market transactions.
-see background information here
-see background information here